A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation

Angelo Antonini, Ioannis U. Isaias, Giorgia Rodolfi, Andrea Landi, Francesca Natuzzi, Chiara Siri, Gianni Pezzoli

Research output: Contribution to journalArticle

Abstract

Prospective comparative long-term data on the effect of deep brain stimulation (DBS) of the subthalamic nucleus (STN) and continuous subcutaneous infusion of apomorphine (CSAI) in patients with advanced Parkinson disease (PD) are lacking. We report 5-year follow-up of 25 PD patients treated with either STN-DBS (n = 13) or CSAI (n = 12) who fulfilled CAPSIT-PD criteria. Cohorts were matched for disease duration and severity of motor complications. Baseline clinical and neuropsychological status did not differ among cohorts. Patients were assessed with the UPDRS, MMSE, HAMD-17 and Neuropsychiatric Inventory (NPI).Twelve subjects reached the 5-year follow-up with STN-DBS (one was lost at follow-up) versus two in the CSAI cohort. Drop-outs with CSAI were due to subcutaneous nodules (n = 2), insufficient control of motor fluctuations and dyskinesia (n = 4), death for unrelated reasons (n = 3) and one was lost at follow-up. Average apomorphine dose at last visit was 83.4 ± 19.2 mg/day and average treatment duration was 30 months. At 1-year as well as at last follow-up (intention-to-treat analysis), both therapies decreased daily off-time but only STN-DBS reduced dyskinesia duration and severity. Decrement of medications was greater with STN-DBS. There was a significant worsening of NPI after STN-DBS, primarily because four subjects developed apathy.

Original languageEnglish
Pages (from-to)579-585
Number of pages7
JournalJournal of Neurology
Volume258
Issue number4
DOIs
Publication statusPublished - Apr 2011

Fingerprint

Subcutaneous Infusions
Subthalamic Nucleus
Deep Brain Stimulation
Apomorphine
Parkinson Disease
Dyskinesias
Apathy
Equipment and Supplies
Intention to Treat Analysis
Therapeutics

Keywords

  • Apomorphine
  • Deep brain stimulation
  • Parkinson disease

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. / Antonini, Angelo; Isaias, Ioannis U.; Rodolfi, Giorgia; Landi, Andrea; Natuzzi, Francesca; Siri, Chiara; Pezzoli, Gianni.

In: Journal of Neurology, Vol. 258, No. 4, 04.2011, p. 579-585.

Research output: Contribution to journalArticle

Antonini, Angelo ; Isaias, Ioannis U. ; Rodolfi, Giorgia ; Landi, Andrea ; Natuzzi, Francesca ; Siri, Chiara ; Pezzoli, Gianni. / A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation. In: Journal of Neurology. 2011 ; Vol. 258, No. 4. pp. 579-585.
@article{23d1433cd89f4d22984903c30ae1e3ba,
title = "A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation",
abstract = "Prospective comparative long-term data on the effect of deep brain stimulation (DBS) of the subthalamic nucleus (STN) and continuous subcutaneous infusion of apomorphine (CSAI) in patients with advanced Parkinson disease (PD) are lacking. We report 5-year follow-up of 25 PD patients treated with either STN-DBS (n = 13) or CSAI (n = 12) who fulfilled CAPSIT-PD criteria. Cohorts were matched for disease duration and severity of motor complications. Baseline clinical and neuropsychological status did not differ among cohorts. Patients were assessed with the UPDRS, MMSE, HAMD-17 and Neuropsychiatric Inventory (NPI).Twelve subjects reached the 5-year follow-up with STN-DBS (one was lost at follow-up) versus two in the CSAI cohort. Drop-outs with CSAI were due to subcutaneous nodules (n = 2), insufficient control of motor fluctuations and dyskinesia (n = 4), death for unrelated reasons (n = 3) and one was lost at follow-up. Average apomorphine dose at last visit was 83.4 ± 19.2 mg/day and average treatment duration was 30 months. At 1-year as well as at last follow-up (intention-to-treat analysis), both therapies decreased daily off-time but only STN-DBS reduced dyskinesia duration and severity. Decrement of medications was greater with STN-DBS. There was a significant worsening of NPI after STN-DBS, primarily because four subjects developed apathy.",
keywords = "Apomorphine, Deep brain stimulation, Parkinson disease",
author = "Angelo Antonini and Isaias, {Ioannis U.} and Giorgia Rodolfi and Andrea Landi and Francesca Natuzzi and Chiara Siri and Gianni Pezzoli",
year = "2011",
month = "4",
doi = "10.1007/s00415-010-5793-z",
language = "English",
volume = "258",
pages = "579--585",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "Dr. Dietrich Steinkopff Verlag GmbH and Co. KG",
number = "4",

}

TY - JOUR

T1 - A 5-year prospective assessment of advanced Parkinson disease patients treated with subcutaneous apomorphine infusion or deep brain stimulation

AU - Antonini, Angelo

AU - Isaias, Ioannis U.

AU - Rodolfi, Giorgia

AU - Landi, Andrea

AU - Natuzzi, Francesca

AU - Siri, Chiara

AU - Pezzoli, Gianni

PY - 2011/4

Y1 - 2011/4

N2 - Prospective comparative long-term data on the effect of deep brain stimulation (DBS) of the subthalamic nucleus (STN) and continuous subcutaneous infusion of apomorphine (CSAI) in patients with advanced Parkinson disease (PD) are lacking. We report 5-year follow-up of 25 PD patients treated with either STN-DBS (n = 13) or CSAI (n = 12) who fulfilled CAPSIT-PD criteria. Cohorts were matched for disease duration and severity of motor complications. Baseline clinical and neuropsychological status did not differ among cohorts. Patients were assessed with the UPDRS, MMSE, HAMD-17 and Neuropsychiatric Inventory (NPI).Twelve subjects reached the 5-year follow-up with STN-DBS (one was lost at follow-up) versus two in the CSAI cohort. Drop-outs with CSAI were due to subcutaneous nodules (n = 2), insufficient control of motor fluctuations and dyskinesia (n = 4), death for unrelated reasons (n = 3) and one was lost at follow-up. Average apomorphine dose at last visit was 83.4 ± 19.2 mg/day and average treatment duration was 30 months. At 1-year as well as at last follow-up (intention-to-treat analysis), both therapies decreased daily off-time but only STN-DBS reduced dyskinesia duration and severity. Decrement of medications was greater with STN-DBS. There was a significant worsening of NPI after STN-DBS, primarily because four subjects developed apathy.

AB - Prospective comparative long-term data on the effect of deep brain stimulation (DBS) of the subthalamic nucleus (STN) and continuous subcutaneous infusion of apomorphine (CSAI) in patients with advanced Parkinson disease (PD) are lacking. We report 5-year follow-up of 25 PD patients treated with either STN-DBS (n = 13) or CSAI (n = 12) who fulfilled CAPSIT-PD criteria. Cohorts were matched for disease duration and severity of motor complications. Baseline clinical and neuropsychological status did not differ among cohorts. Patients were assessed with the UPDRS, MMSE, HAMD-17 and Neuropsychiatric Inventory (NPI).Twelve subjects reached the 5-year follow-up with STN-DBS (one was lost at follow-up) versus two in the CSAI cohort. Drop-outs with CSAI were due to subcutaneous nodules (n = 2), insufficient control of motor fluctuations and dyskinesia (n = 4), death for unrelated reasons (n = 3) and one was lost at follow-up. Average apomorphine dose at last visit was 83.4 ± 19.2 mg/day and average treatment duration was 30 months. At 1-year as well as at last follow-up (intention-to-treat analysis), both therapies decreased daily off-time but only STN-DBS reduced dyskinesia duration and severity. Decrement of medications was greater with STN-DBS. There was a significant worsening of NPI after STN-DBS, primarily because four subjects developed apathy.

KW - Apomorphine

KW - Deep brain stimulation

KW - Parkinson disease

UR - http://www.scopus.com/inward/record.url?scp=79953806050&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953806050&partnerID=8YFLogxK

U2 - 10.1007/s00415-010-5793-z

DO - 10.1007/s00415-010-5793-z

M3 - Article

C2 - 20972684

AN - SCOPUS:79953806050

VL - 258

SP - 579

EP - 585

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

IS - 4

ER -